Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The return on equity (ROE) is N/A as of the fiscal period ended Tuesday, March 31, 2026.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q1 FY2026 (2026-03-31): -555.19%.
RETURN ON EQUITY (ROE)
N/A
RETURN ON EQUITY (ROE) AVG TTM
-314.02%
RETURN ON EQUITY (ROE) AVG 3Y
-244.50%
RETURN ON EQUITY (ROE) AVG 5Y
-203.15%
RETURN ON EQUITY (ROE) AVG 10Y
-155.51%
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Processa Pharmaceuticals, Inc.
Market Cap
$4.11M
Return on Equity (ROE)
N/A
TTM Avg
-314.02%
3Y Avg
-244.50%
5Y Avg
-203.15%
Market Cap
$4.13M
Return on Equity (ROE)
N/A
TTM Avg
-201.28%
3Y Avg
-1309.54%
5Y Avg
-838.52%
Market Cap
$4.23M
Return on Equity (ROE)
-184.04%
TTM Avg
9542.92%
3Y Avg
4740.03%
5Y Avg
3155.09%
Market Cap
$3.98M
Return on Equity (ROE)
-437.15%
TTM Avg
-328.44%
3Y Avg
-188.67%
5Y Avg
-533.64%
Market Cap
$4.30M
Return on Equity (ROE)
-424.89%
TTM Avg
-156.14%
3Y Avg
-97.37%
5Y Avg
-86.32%
Market Cap
$3.90M
Return on Equity (ROE)
-310.33%
TTM Avg
-204.84%
3Y Avg
-115.20%
5Y Avg
-69.88%
Market Cap
$3.79M
Return on Equity (ROE)
N/A
TTM Avg
5741.84%
3Y Avg
2797.55%
5Y Avg
1847.94%
Market Cap
$3.72M
Return on Equity (ROE)
-383.03%
TTM Avg
-1602.50%
3Y Avg
-1094.59%
5Y Avg
-783.90%
Market Cap
$4.55M
Return on Equity (ROE)
-239.95%
TTM Avg
-454.28%
3Y Avg
-297.70%
5Y Avg
-194.53%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Processa Pharmaceuticals, Inc. (PCSA) | $4.11M | N/A | -314.02% | -244.50% | -203.15% |
| GRI Bio, Inc. (GRI)vs › | $4.13M | N/A | -201.28% | -1309.54% | -838.52% |
| 20/20 Biolabs Inc. (AIDX)vs › | $4.23M | -184.04% | 9542.92% | 4740.03% | 3155.09% |
| Aptevo Therapeutics Inc. (APVO)vs › | $3.98M | -437.15% | -328.44% | -188.67% | -533.64% |
| CollPlant Biotechnologies Ltd. (CLGN)vs › | $4.30M | -424.89% | -156.14% | -97.37% | -86.32% |
| 60 Degrees Pharmaceuticals, Inc. (SXTP)vs › | $3.90M | -310.33% | -204.84% | -115.20% | -69.88% |
| Evogene Ltd. (EVGN)vs › | $3.79M | N/A | 5741.84% | 2797.55% | 1847.94% |
| Ernexa Therapeutics Inc. (ERNA)vs › | $3.72M | -383.03% | -1602.50% | -1094.59% | -783.90% |
| Dermata Therapeutics, Inc. (DRMA)vs › | $4.55M | -239.95% | -454.28% | -297.70% | -194.53% |
| Cadrenal Therapeutics, Inc. Common Stock (CVKD)vs › | $3.64M | -282.13% | -313.25% | -153.55% | -153.55% |
ROE
N/A
ROA
-649.3%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-03-31 | -555.19% |
| 2025-12-31 | -243.20% |
| 2025-09-30 | -221.71% |
| 2025-06-30 | -210.93% |
| 2025-03-31 | -339.08% |
| 2024-12-31 | -698.64% |
| 2024-09-30 | -309.78% |
| 2024-06-30 | -169.72% |
| 2024-03-31 | -110.61% |
| 2023-12-31 | -222.91% |
| 2023-09-30 | -303.14% |
| 2023-06-30 | -280.22% |
| 2023-03-31 | -278.23% |
| 2022-12-31 | -367.09% |
| 2022-09-30 | -102.06% |
| 2022-06-30 | -72.52% |
| 2022-03-31 | -54.03% |
| 2021-12-31 | -44.84% |
| 2021-09-30 | -66.08% |
| 2021-06-30 | -61.77% |
| 2021-03-31 | -49.91% |
| 2020-12-31 | -62.83% |
| 2020-09-30 | -98.67% |
| 2020-06-30 | -49.23% |
| 2020-03-31 | -48.12% |
| 2019-12-31 | -41.91% |
| 2019-09-30 | -36.82% |
| 2019-06-30 | -37.43% |
| 2019-03-31 | -37.47% |
| 2018-12-31 | -38.81% |
| 2018-09-30 | -44.63% |
| 2018-06-30 | -35.74% |
| 2018-03-31 | -39.55% |
| 2017-12-31 | -497.45% |
| 2015-03-31 | -545.26% |
| 2014-12-31 | -374.71% |
| 2014-06-30 | -597.32% |
| 2014-03-31 | -349.32% |
| 2013-12-31 | -183.66% |
| 2013-09-30 | -128.40% |
| 2013-06-30 | -290.57% |
| 2013-03-31 | -154.65% |
| 2012-12-31 | -95.54% |
| 2012-09-30 | -73.87% |
